Form 4: Tevogen Bio Holdings Director Receives Stock Grant

Tevogen Bio Holdings Inc. reports a stock grant to Director Susan M. Podlogar, with vesting tied to significant revenue milestones.

Summary

• Susan M. Podlogar, a Director at Tevogen Bio Holdings Inc., received a grant of 40,000 shares of common stock on July 10, 2026.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The shares vest in three equal installments, contingent on the company achieving specific aggregate revenue targets and the reporting person remaining in service.
• The revenue targets are $50 million for the first installment, $100 million for the second, and $150 million for the third, measured from the grant date.
• Vesting dates are tied to the first, second, and third anniversaries of the grant date, respectively, provided revenue and service conditions are met.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it details a standard stock grant to a director with performance-based vesting, rather than reporting on operational or financial results.

Positives

• Director Susan M. Podlogar received a significant stock grant, indicating continued investment in key personnel.
• The incentive plan is structured to reward the company's growth, with vesting tied to substantial revenue milestones ($50M, $100M, $150M).

Negatives

• The vesting of the stock grant is contingent on achieving significant revenue targets, which may not be met.
• The reporting person must remain in service with the Issuer on the applicable vesting date for the shares to vest.

Risks

• Failure to achieve the specified aggregate revenue targets ($50 million, $100 million, $150 million) by the respective vesting dates will result in the forfeiture of unvested shares.
• The reporting person's continued employment with Tevogen Bio Holdings Inc. is a condition for vesting.

Future Outlook

The future outlook for the vesting of these shares is directly tied to Tevogen Bio Holdings Inc.'s ability to achieve significant revenue growth, with specific targets set for $50 million, $100 million, and $150 million in aggregate revenue since the grant date.

Industry Context

StockSavvy.ai notes that performance-based equity grants tied to revenue milestones are a common practice in the biotechnology sector to align executive and director compensation with company growth and shareholder value.

Stakeholder Impact

• Shareholders: The grant aligns director compensation with company performance, potentially leading to increased shareholder value if revenue targets are met.
• Employees: The incentive structure may motivate broader company efforts towards achieving revenue goals.
• Management: The grant reinforces the importance of revenue generation for executive and director compensation.

Next Steps

• Monitor Tevogen Bio Holdings Inc.'s revenue generation to assess progress towards the vesting milestones.
• Observe the continued service of Susan M. Podlogar with the Issuer.

Key Dates

Keywords

Tevogen Bio Holdings, Susan M. Podlogar, Stock Grant, Omnibus Incentive Plan, Restricted Stock, Vesting Schedule, Revenue Milestones, Director Compensation, SEC Form 4